Millennium Management LLC Buys New Stake in Theravance Biopharma (TBPH)

Millennium Management LLC bought a new position in shares of Theravance Biopharma (NASDAQ:TBPH) in the 4th quarter, according to its most recent 13F filing with the SEC. The fund bought 15,038 shares of the biopharmaceutical company’s stock, valued at approximately $419,000.

Other institutional investors also recently bought and sold shares of the company. Landscape Capital Management L.L.C. acquired a new position in shares of Theravance Biopharma during the 4th quarter worth about $313,000. Teacher Retirement System of Texas acquired a new position in shares of Theravance Biopharma during the 4th quarter worth about $416,000. Virtus Fund Advisers LLC acquired a new position in shares of Theravance Biopharma during the 4th quarter worth about $974,000. Alps Advisors Inc. grew its position in shares of Theravance Biopharma by 13.1% during the 4th quarter. Alps Advisors Inc. now owns 59,951 shares of the biopharmaceutical company’s stock worth $1,672,000 after buying an additional 6,938 shares during the period. Finally, Deutsche Bank AG grew its position in shares of Theravance Biopharma by 82.4% in the 4th quarter. Deutsche Bank AG now owns 108,750 shares of the biopharmaceutical company’s stock valued at $3,031,000 after purchasing an additional 49,137 shares during the period. Institutional investors own 84.85% of the company’s stock.

TBPH has been the subject of several research analyst reports. BidaskClub upgraded Theravance Biopharma from a “strong sell” rating to a “sell” rating in a research report on Saturday, January 20th. Leerink Swann boosted their price objective on Theravance Biopharma from $45.00 to $48.00 and gave the company an “outperform” rating in a research report on Thursday, February 8th. Cantor Fitzgerald set a $55.00 price objective on Theravance Biopharma and gave the company a “buy” rating in a research report on Tuesday, February 27th. ValuEngine lowered Theravance Biopharma from a “hold” rating to a “sell” rating in a research report on Wednesday, March 7th. Finally, Piper Jaffray reiterated an “overweight” rating and issued a $45.00 price objective on shares of Theravance Biopharma in a research report on Thursday, March 29th. Three analysts have rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company. The company has an average rating of “Hold” and an average target price of $39.29.

Shares of Theravance Biopharma opened at $24.48 on Friday, according to MarketBeat Ratings. The company has a debt-to-equity ratio of 3.53, a current ratio of 4.25 and a quick ratio of 4.08. Theravance Biopharma has a 52-week low of $23.98 and a 52-week high of $24.71. The company has a market capitalization of $1.35 billion, a P/E ratio of -4.49 and a beta of 1.81.

Theravance Biopharma (NASDAQ:TBPH) last released its earnings results on Tuesday, May 8th. The biopharmaceutical company reported ($1.22) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.26) by $0.04. The firm had revenue of $8.32 million for the quarter, compared to analysts’ expectations of $5.74 million. Theravance Biopharma had a negative return on equity of 188.96% and a negative net margin of 1,383.47%. equities analysts forecast that Theravance Biopharma will post -4.8 EPS for the current year.

About Theravance Biopharma

Theravance Biopharma, Inc, a diversified biopharmaceutical company, discovers, develops, and commercializes human therapeutics. The company offers VIBATIV (telavancin), a bactericidal, once-daily injectable antibiotic to treat patients with infections due to Staphylococcus aureus and other Gram-positive bacteria.

Institutional Ownership by Quarter for Theravance Biopharma (NASDAQ:TBPH)

Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Expeditors International  – Analysts’ Weekly Ratings Updates
Expeditors International – Analysts’ Weekly Ratings Updates
Ranger Energy Services  – Research Analysts’ Recent Ratings Changes
Ranger Energy Services – Research Analysts’ Recent Ratings Changes
Geode Capital Management LLC Has $2.32 Billion Stake in Visa
Geode Capital Management LLC Has $2.32 Billion Stake in Visa
Steel Canyon Capital LLC Sells 3,200 Shares of Alphabet Inc.
Steel Canyon Capital LLC Sells 3,200 Shares of Alphabet Inc.
Millennium Management LLC Trims Stake in TransEnterix, Inc.
Millennium Management LLC Trims Stake in TransEnterix, Inc.
FDx Advisors Inc. Lowers Holdings in PRA Group
FDx Advisors Inc. Lowers Holdings in PRA Group


Leave a Reply

© 2006-2018 Ticker Report. Google+.